PropThink: Sunesis Increases Sample Size and Receives $25M in Conjunction
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) are rebounding from late losses on Monday, up 50% in premarket trading after the company announced an increase in the size of its lead phase 3 clinical trial, recommended by an independent Data and Safety Monitoring Board (DSMB). More importantly, however, the sample increase triggers a $25M investment from Royalty Pharma. According to an agreement reached in March, Royalty Pharma is obligated to purchase a Revenue Participation Right (RPR) from Sunesis if the trial's DSMB moves to increase the patient sample in the VALOR Trial. The decision comes after a planned interim analysis of vosaroxin, which is in the phase 3 trial for the treatment of acute myeloid leukemia and a Phase 2 trial for ovarian cancer. The RPR gives Royalty Pharma a 6.75% royalty rate on net sales of vosaroxin until the latter of certain patent expirations, market exclusivity, or ten years on the market. The agreement also grants Royalty Pharma two five-year warrants for one million shares each. The investment is a nod of confidence to the company's only product and supports institutional belief in FDA approval of the orphan drug.
It is worth noting that today's gains are partially offset by a 21% loss before the close on Monday. Shares are up 16% on the week, from $3.40 to $3.96 just before Tuesday's opening bell. SNSS is trading at twice its normal average and is up 300% in 2012.
Click here to see this article at PropThink.com.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter, or visit us at http://www.propthink.com.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: PropThink via Thomson Reuters ONE